Literature DB >> 24329535

Inflammation in neurodegenerative diseases--an update.

Sandra Amor1, Laura A N Peferoen, Daphne Y S Vogel, Marjolein Breur, Paul van der Valk, David Baker, Johannes M van Noort.   

Abstract

Neurodegeneration, the progressive dysfunction and loss of neurons in the central nervous system (CNS), is the major cause of cognitive and motor dysfunction. While neuronal degeneration is well-known in Alzheimer's and Parkinson's diseases, it is also observed in neurotrophic infections, traumatic brain and spinal cord injury, stroke, neoplastic disorders, prion diseases, multiple sclerosis and amyotrophic lateral sclerosis, as well as neuropsychiatric disorders and genetic disorders. A common link between these diseases is chronic activation of innate immune responses including those mediated by microglia, the resident CNS macrophages. Such activation can trigger neurotoxic pathways leading to progressive degeneration. Yet, microglia are also crucial for controlling inflammatory processes, and repair and regeneration. The adaptive immune response is implicated in neurodegenerative diseases contributing to tissue damage, but also plays important roles in resolving inflammation and mediating neuroprotection and repair. The growing awareness that the immune system is inextricably involved in mediating damage as well as regeneration and repair in neurodegenerative disorders, has prompted novel approaches to modulate the immune system, although it remains whether these approaches can be used in humans. Additional factors in humans include ageing and exposure to environmental factors such as systemic infections that provide additional clues that may be human specific and therefore difficult to translate from animal models. Nevertheless, a better understanding of how immune responses are involved in neuronal damage and regeneration, as reviewed here, will be essential to develop effective therapies to improve quality of life, and mitigate the personal, economic and social impact of these diseases.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  central nervous system; inflammation; innate; neurodegeneration; neuroprotection; repair

Mesh:

Year:  2014        PMID: 24329535      PMCID: PMC4008224          DOI: 10.1111/imm.12233

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  108 in total

Review 1.  Immunology of neuromyelitis optica: a T cell-B cell collaboration.

Authors:  Meike Mitsdoerffer; Vijay Kuchroo; Thomas Korn
Journal:  Ann N Y Acad Sci       Date:  2013-04       Impact factor: 5.691

Review 2.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

3.  Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation.

Authors:  Arianna Bellucci; Orso Bugiani; Bernardino Ghetti; Maria Grazia Spillantini
Journal:  Neurodegener Dis       Date:  2011-01-05       Impact factor: 2.977

Review 4.  Complement activation in the injured central nervous system: another dual-edged sword?

Authors:  Faith H Brennan; Aileen J Anderson; Stephen M Taylor; Trent M Woodruff; Marc J Ruitenberg
Journal:  J Neuroinflammation       Date:  2012-06-21       Impact factor: 8.322

5.  An update of animal models of Alzheimer disease with a reevaluation of plaque depositions.

Authors:  Jung-Eun Lee; Pyung-Lim Han
Journal:  Exp Neurobiol       Date:  2013-06-27       Impact factor: 3.261

6.  Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis.

Authors:  Fabiola Puentes; Baukje J van der Star; Marion Victor; Markus Kipp; Cordian Beyer; Regina Peferoen-Baert; Kimberley Ummenthum; Gareth Pryce; Wouter Gerritsen; Ruth Huizinga; Arie Reijerkerk; Paul van der Valk; David Baker; Sandra Amor
Journal:  J Neuroinflammation       Date:  2013-09-22       Impact factor: 8.322

7.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Authors:  Gareth Pryce; Zubair Ahmed; Deborah J R Hankey; Samuel J Jackson; J Ludovic Croxford; Jennifer M Pocock; Catherine Ledent; Axel Petzold; Alan J Thompson; Gavin Giovannoni; M Louise Cuzner; David Baker
Journal:  Brain       Date:  2003-07-22       Impact factor: 13.501

Review 8.  Biozzi mice: of mice and human neurological diseases.

Authors:  Sandra Amor; Paul A Smith; Bert 't Hart; David Baker
Journal:  J Neuroimmunol       Date:  2005-08       Impact factor: 3.478

Review 9.  The wobbler mouse, an ALS animal model.

Authors:  Jakob Maximilian Moser; Paolo Bigini; Thomas Schmitt-John
Journal:  Mol Genet Genomics       Date:  2013-03-29       Impact factor: 3.291

10.  Alterations in gene expression in Caenorhabditis elegans associated with organophosphate pesticide intoxication and recovery.

Authors:  John A Lewis; Elizabeth A Gehman; Christine E Baer; David A Jackson
Journal:  BMC Genomics       Date:  2013-04-30       Impact factor: 3.969

View more
  173 in total

1.  Sumoylation of p35 modulates p35/cyclin-dependent kinase (Cdk) 5 complex activity.

Authors:  Anja Büchner; Petranka Krumova; Sundar Ganesan; Mathias Bähr; Katrin Eckermann; Jochen H Weishaupt
Journal:  Neuromolecular Med       Date:  2014-11-13       Impact factor: 3.843

2.  Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol.

Authors:  Catherine A S Deane; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2016-06-08       Impact factor: 3.667

Review 3.  PET and MR imaging of neuroinflammation in hepatic encephalopathy.

Authors:  Yun Yan Su; Gui Fen Yang; Guang Ming Lu; Shawn Wu; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2014-12-17       Impact factor: 3.584

Review 4.  Salivary Inflammatory Molecules as Biomarkers of Sleep Alterations: A Scoping Review.

Authors:  Vanessa Ibáñez-Del Valle; Rut Navarro-Martínez; Maria Luisa Ballestar-Tarin; Omar Cauli
Journal:  Diagnostics (Basel)       Date:  2021-02-10

5.  Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Authors:  James A Carroll; Brent Race; Katie Phillips; James F Striebel; Bruce Chesebro
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

Review 6.  Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy.

Authors:  Su M Metcalfe; Sean Bickerton; Tarek Fahmy
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 7.  Role of MCP-1 and CCR2 in alcohol neurotoxicity.

Authors:  Kai Zhang; Jia Luo
Journal:  Pharmacol Res       Date:  2018-11-22       Impact factor: 7.658

8.  TET repression and increased DNMT activity synergistically induce aberrant DNA methylation.

Authors:  Hideyuki Takeshima; Tohru Niwa; Satoshi Yamashita; Takeji Takamura-Enya; Naoko Iida; Mika Wakabayashi; Sohachi Nanjo; Masanobu Abe; Toshiro Sugiyama; Young-Joon Kim; Toshikazu Ushijima
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

9.  Normobaric intermittent hypoxic training regulates microglia phenotype and enhances phagocytic activity.

Authors:  Genell Tantingco; Myoung-Gwi Ryou
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-16

10.  Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ -activated BV-2 microglia cells.

Authors:  Makini K Cobourne-Duval; Equar Taka; Patricia Mendonca; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-05-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.